

Peptides Bearing Multiple Post-Translational Modifications as Antigenic Targets for Severe Rheumatoid Arthritis Patients.

Cristina García-Moreno ¹, María J. Gómara ¹, Raúl Castellanos-Moreira ², Raimon Sanmartí ² and Isabel Haro ^{1,*}

¹ Unit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas (IQAC-CSIC), Jordi Girona 18-26, Barcelona 08034, Spain.

² Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Villarroel 170, Barcelona 08036, Spain.

* Correspondence: isabel.haro@iqac.csic.es

Table S1. Comparison of autoantibodies presenting erosive-RA (yes or not)

	erosive (n=89)	non- erosive (n=89)
CFFCHP1		
anti-CFFCHP1-IgG positive (%)	53 (59.6)	51 (57.3)
median titer anti-CFFCHP1 AU/mL (IQR)	54 (676)	62 (307)
anti-CFFCHP1-IgA positive (%)	33 (37.1)	31 (34.8)
median titer anti-CFFCHP1 AU/mL (IQR)	8 (91)	4 (41)
anti-CFFCHP1-IgM positive (%)	20 (22.5)	17 (19.1)
median titer anti-CFFCHP1 AU/mL (IQR)	0 (43)	0 (35)
CFFCHP2		
anti-CFFCHP2-IgG positive (%)	52 (58.4)	50 (56.2)
median titer anti-CFFCHP2 AU/mL (IQR)	42 (769)	74 (403)
anti-CFFCHP2-IgA positive (%)	35 (39.3)	35 (39.3)
median titer anti-CFFCHP2 AU/mL (IQR)	10 (90)	12 (43)
anti-CFFCHP2-IgM positive (%)	23 (25.8)	18 (20.2)
median titer anti-CFFCHP2 AU/mL (IQR)	0 (79)	0 (39)
CFFCHP3		
anti-CFFCHP3-IgG positive (%)	52 (58.4)	50 (56.2)
median titer anti-CFFCHP3 AU/mL (IQR)	67 (727)	70 (417)
anti-CFFCHP3-IgA positive (%)	30 (33.7)	34 (38.2)
median titer anti-CFFCHP3 AU/mL (IQR)	18 (94)	18 (39)
anti-CFFCHP3-IgM positive (%)	23 (25.8)	18 (20.2)
median titer anti-CFFCHP3 AU/mL (IQR)	0 (86)	0 (54)
CFFCHAP		
anti-CFFCHP3-IgG positive (%)	47 (52.8)	48 (53.9)
median titer anti-CFFCHP3 AU/mL (IQR)	30 (796)	31 (173)
anti-CFFCHP3-IgA positive (%)	31 (34.8)	27 (30.3)
median titer anti-CFFCHP3 AU/mL (IQR)	11 (48)	0 (33)
anti-CFFCHP3-IgM positive (%)	20 (22.5)	21 (23.6)
median titer anti-CFFCHP3 AU/mL (IQR)	0 (37)	0 (26)

The differences were not significative




Figure S1. Intra-assay and inter-assay variability for biotinylated and non-biotinylated CFFCP1 peptide.